Clinical characteristics, management, and outcomes of nivolumab-associated pituitary toxicity: a pooled analysis of published case reports and case series
Open Access
- 21 October 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1929591
Abstract
Objective: To summarize the clinical features, diagnosis, management, and outcomes of nivolumab-associated pituitary toxicity. Methods: We conducted a pooled analysis of published case reports and case series describing nivolumab-associated pituitary toxicity. PubMed, Embase, Web of Science Core Collection, CNKI, and Wanfang Data were searched from inception to June 8, 2026, supplemented by reference-list screening. Reports with extractable individual patient data describing nivolumab-associated hypophysitis, isolated adrenocorticotropic hormone (ACTH) deficiency, or central/secondary adrenal insufficiency were included. Combination immune checkpoint inhibitor therapy, insufficient data, and duplicate reports were excluded. Data were extracted per patient. Continuous and categorical variables are presented as median (range) and n/N (%), respectively. Results: Forty-five independent patients from 43 reports were included; 33 (73.3%) were male, and median age was 68 years (39–85). Toxicity occurred after a median of 9 nivolumab cycles (n=40; range, 1–33); 8 patients (17.8%) developed symptoms after discontinuation, with a median delay of 24 weeks (4–56). Fatigue (41/44, 93.2%), anorexia (32/45, 71.1%), and nausea/vomiting (23/44, 52.3%) predominated. Hyponatremia occurred in 24/33 patients (72.7%). ACTH was low in 38/44 patients (86.4%) and inappropriately normal in 6/44 (13.6%) despite low cortisol; basal cortisol was reduced in 43/44 (97.7%). Pituitary MRI abnormalities were reported in 11/41 patients (26.8%). Hydrocortisone was the most frequently used replacement therapy, and symptoms improved in 44/45 patients (97.8%). Among 29 patients with hormonal follow-up, 2 (6.9%) had partial ACTH–cortisol axis recovery; none had complete recovery. No recurrence was reported among six patients rechallenged with nivolumab. Conclusion: Nivolumab-associated pituitary toxicity mainly affects the ACTH–cortisol axis and may present without MRI abnormalities. Prompt assessment of cortisol, ACTH, and electrolytes is warranted in symptomatic patients.Keywords
This publication has 28 references indexed in Scilit:
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Isolated ACTH deficiency induced by cancer immunotherapy: a systematic reviewPituitary, 2021
- Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trialThe Lancet Oncology, 2019
- Immune-Related Adverse Events Associated with Immune Checkpoint BlockadeNew England Journal of Medicine, 2018
- Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical managementCancer, 2018
- Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathiesNature Reviews Endocrinology, 2017
- Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 BlockadeThe American Journal of Pathology, 2016
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012